Welcome to our dedicated page for TELA Bio news (Ticker: TELA), a resource for investors and traders seeking the latest updates and insights on TELA Bio stock.
TELA Bio, Inc. (NASDAQ: TELA) is a pioneering medical technology company based in Malvern, Pennsylvania, dedicated to transforming the field of soft tissue reconstruction. With a mission to provide advanced, cost-effective solutions, TELA Bio focuses on enhancing clinical outcomes by prioritizing the preservation and restoration of a patient's own anatomy.
The company offers two primary product lines: OviTex and OviTex PRS Reinforced Tissue Matrices. These products are designed to improve clinical outcomes and reduce costs in hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery. OviTex, a reinforced tissue matrix, leverages the body's natural healing response while minimizing long-term exposure to synthetic materials.
In recent developments, TELA Bio has launched LIQUIFIX, the first approved adhesive-based product for affixing mesh without penetrating patient tissue. This innovation underscores TELA Bio's commitment to providing surgeons with cutting-edge, economically viable solutions that align with modern clinical practices.
Financially, TELA Bio is experiencing significant growth. For the first quarter of 2024, the company reported a revenue increase of 39% year-over-year, reaching $16.6 million. This growth is attributed to a mature sales force, strategic product launches, and an expanding customer base. Despite operational losses, the company achieved a notable decrease in net loss, demonstrating improved financial management and operational efficiency.
Moreover, TELA Bio actively collaborates with leading surgeons to continuously innovate and address the unmet needs in soft tissue repair. The company's partnership with experts ensures that its products meet the highest standards of efficacy and safety.
For the latest updates, TELA Bio frequently hosts earnings conference calls and webcasts, providing valuable insights into its financial performance and strategic initiatives. Investors and stakeholders can access these resources via the investor section of the company's website.
In summary, TELA Bio, Inc. is a dynamic and forward-looking company poised to make significant advancements in medical technology. By combining innovation with practical solutions, TELA Bio aims to reinvigorate the soft tissue reconstruction market and provide substantial benefits to hospitals, surgeons, and patients alike.
TELA Bio, Inc. (Nasdaq: TELA) reported preliminary unaudited financial results for Q4 and full year 2020. Fourth quarter revenue is projected to be $5.5-5.7 million, a 13-17% increase from Q4 2019, while full-year revenue is expected to reach $18.0-18.2 million, up 17-18% from 2019. Cash and cash equivalents are anticipated at $74.4 million as of December 31, 2020. Although the COVID-19 pandemic has impacted procedural volumes and revenue growth, TELA has made progress in expanding its commercial operations and product offerings.
MALVERN, Pa., Jan. 6, 2021 – TELA Bio announces participation in the 23rd Annual Needham Virtual Growth Conference. The management is set to present on January 15, 2021, at 2:45 PM EST. Interested individuals can access the live and archived webcast at ir.telabio.com. TELA Bio focuses on developing tissue reinforcement materials for soft tissue reconstruction, aiming to address unmet medical needs.
TELA Bio, Inc. (Nasdaq: TELA) has appointed Bruce Freedman, M.D., FACS as Vice President of Clinical Development. With over 30 years in hernia repair, Dr. Freedman advocates for natural hernia mesh alternatives, specifically the OviTex Reinforced Tissue Matrix, designed to reduce foreign body responses. He will leverage his experience to promote the clinical and financial benefits of TELA's innovative products to surgeons and hospital administrators. This strategic hire aims to enhance patient access to safer hernia repair options, distinguishing TELA from larger competitors.
TELA Bio, Inc. is preparing to participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. The company specializes in medical technology, developing innovative tissue reinforcement materials for soft tissue reconstruction. Their products aim to address gaps in existing biologics and reduce the long-term risks of permanent synthetic materials. Interested parties can access the fireside chat presentation link through TELA's investor relations page.
TELA Bio, Inc. (NASDAQ: TELA) reported third-quarter 2020 revenues of $5.3 million, a 34% increase year-over-year. This growth was tempered by lower than expected procedural volumes due to COVID-19. Gross profit reached $3.3 million, representing a 62% margin, down from 66% the previous year. Operating expenses rose to $10.2 million, leading to a loss from operations of $6.9 million and a net loss of $7.7 million. The company has $81.5 million in cash. TELA did not provide 2020 financial guidance due to pandemic-related uncertainties.
MALVERN, Pa., Nov. 10, 2020 – TELA Bio, a medical technology company, announced its participation in two investor conferences. Management will present at the Jefferies Virtual London Healthcare Conference on November 17, 2020, at 10:15 AM EST and the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020, at 10:30 AM EST. Live audio webcasts will be available on the company’s website. TELA Bio focuses on developing innovative tissue reinforcement materials for soft tissue reconstruction, backed by extensive scientific research.
TELA Bio, Inc. (Nasdaq: TELA), a medical technology firm, will report its 2020 third quarter financial results on November 11, 2020. The company focuses on developing innovative tissue reinforcement materials for soft tissue reconstruction. A conference call will take place at 4:30 p.m. ET on the same day for management to discuss financial results and provide corporate updates. TELA Bio's products aim to improve existing biologics, reducing long-term exposure to synthetic materials, supported by extensive pre-clinical research.
TELA Bio, Inc. announced positive findings from the BRAVO study presented at the Americas Hernia Society Annual Meeting. The data demonstrated a low incidence of surgical site infections and no hernia recurrences at 30 days post-operation using OviTex in ventral hernia repairs. The study involved 85 subjects, with 50% being obese and 16% having a history of surgical infections. Long-term results showed no hernia recurrences among the initial 20 subjects after two years. TELA's OviTex aims to address unmet needs in soft tissue reconstruction.
TELA Bio reported a revenue of $3.5 million for Q2 2020, marking a 6% increase from Q2 2019. Despite this growth, procedural volume declines due to the COVID-19 pandemic impacted results. Gross profit rose to $2.1 million, representing 59% of revenue, up from 58% in the previous year. Operating expenses increased to $7.3 million, leading to a loss from operations of $5.2 million. The company completed a public offering, raising approximately $45 million. Due to COVID-19 uncertainty, TELA will not provide 2020 financial guidance.
TELA Bio, Inc. (NASDAQ: TELA), a medical technology company specializing in tissue reinforcement materials, will participate in the Canaccord Genuity 40th Annual Growth Conference from August 11-13, 2020. Management is set to present on August 13 at 1:30 p.m. ET. The conference will be held virtually, and interested parties can access the live webcast through the company's website. TELA Bio focuses on addressing unmet needs in soft tissue reconstruction with innovative products backed by extensive research.
FAQ
What is the current stock price of TELA Bio (TELA)?
What is the market cap of TELA Bio (TELA)?
What does TELA Bio, Inc. specialize in?
What are the main products offered by TELA Bio?
Where is TELA Bio, Inc. located?
How has TELA Bio performed financially recently?
What recent product has TELA Bio launched?
How can investors stay updated on TELA Bio's performance?
What is OviTex?
Which market needs does TELA Bio aim to address?
Is TELA Bio publicly traded?
Who can be contacted for investor relations at TELA Bio?
